24 Million Americans Lost GLP-1 Coverage — And It’s Getting Worse
An NPR investigation published April 15, 2026 paints a grim picture: 12 million people lost coverage for Zepbound, and another 12 million lost coverage for Wegovy over the past year. That’s 24 million patients caught between medications that work and insurance companies that won’t pay for them.
The math is brutal. A teacher in Massachusetts watched her insurance drop Zepbound in July, switched to Wegovy at the same copay, then lost Wegovy coverage in October. Her premium went up 20%. The insurer blamed expensive GLP-1s — the same drugs they stopped covering.
What’s Actually Happening
Pharmacy benefit managers (PBMs) like CVS Caremark are playing the drug companies against each other. CVS dropped Eli Lilly’s Zepbound from its standard formulary in favor of Novo Nordisk’s Wegovy. The stated reason: “competition drives down costs.” The result for patients: coverage roulette.
According to GoodRx research, the coverage landscape is getting more restrictive, not less. Even when plans technically cover a GLP-1, the barriers are stacking up:
- Prior authorization required for 88% of covered plans
- BMI thresholds of 40+ — well above the obesity threshold of 30
- Step therapy requiring months on cheaper drugs first
- High cost-sharing leaving patients paying hundreds even with “coverage”
Dr. Catherine Varney, obesity medicine director at UVA Health, told NPR she now spends more time as a “financial planner” than a physician. 60% of her patients pay out of pocket.
The Compounding Escape Route
The NPR story ends where a growing number of patients are landing: compounding pharmacies. The teacher profiled in the story now pays about $300/month for compounded medication, compared to Eli Lilly’s $450 cash price for brand-name Zepbound.
Compounded semaglutide and tirzepatide use the same active ingredients as the brand-name versions but are made by specialized pharmacies, not the drug manufacturers. Prices typically range from $129 to $497 per month depending on the provider and dose.
Several telehealth platforms now specialize in GLP-1 access through compounding:
- Hims — compounded semaglutide starting around $199/month, includes medical consultation and shipping
- Ro — structured weight loss program with compounded options
- Henry Meds — compounded tirzepatide and semaglutide with monthly monitoring
A Lifeline for Medicare Patients
There is one piece of genuinely good news. Starting July 1, 2026, Medicare’s new GLP-1 Bridge program will cover Wegovy and Zepbound for obesity at a $50 copay. The program runs through December 31, 2026, and eligibility is based on BMI criteria through Medicare Part D.
If you’re on Medicare, this could save you hundreds per month. Check your eligibility with our Medicare Bridge Calculator →
What You Can Do Right Now
If you’ve lost coverage or are facing a denial, you have more options than you think:
1. Appeal the Denial
This is the most underused tool available. 60-80% of GLP-1 insurance appeals succeed, but most patients never try. Your doctor can write a Letter of Medical Necessity that makes the case for coverage based on your BMI, comorbidities, and treatment history.
Generate a custom appeal letter →
2. Check Manufacturer Savings Programs
Both Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) offer savings cards that can reduce copays to as low as $25/month for commercially insured patients. These don’t help if your plan excludes the drug entirely, but they’re worth checking.
3. Explore Compounded Alternatives
If branded drugs are out of reach, compounded versions from licensed pharmacies cost a fraction of the price. Our branded vs. compounded comparison breaks down the quality, cost, and risk tradeoffs.
4. Use Our Decision Wizard
Not sure which path is right for you? Answer 3 quick questions and get a personalized recommendation.
The Bigger Picture
The insurance industry is making a bet that if they make GLP-1s hard enough to access, demand will moderate and costs will come down. Patients are the ones absorbing that bet. As one advocacy leader told NPR: “Every insurance carrier is just making it up — making up the policy, the limitation, the restriction on eligibility in the way that they want to.”
Until coverage catches up with clinical evidence, patients need to be their own advocates. The tools exist — appeals, savings programs, compounding, Medicare coverage. The information gap is the real barrier, and that’s what we’re here to close.
This article references reporting by Sydney Lupkin for NPR, published April 15, 2026. GLP-1 Price Guide is an independent resource and is not affiliated with NPR, Novo Nordisk, or Eli Lilly.
